Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Conditions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 75
- Registration Number
- NCT05272826
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 72
- Registration Number
- NCT04786028
- Locations
- 🇨🇦
The Ottawa Hospital General Campus, Ottawa, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Nova Scotia Health - QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Canadian Myeloma Research Group
- Registration Number
- NCT04258683
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada
🇨🇦The Moncton Hospital, Moncton, New Brunswick, Canada
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 120
- Registration Number
- NCT03715478
- Locations
- 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT03697629
- Locations
- 🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 120
- Registration Number
- NCT03215524
- Locations
- 🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦CrossCancer Institute, Edmonton, Alberta, Canada
🇨🇦Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada